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CRM1

:   chromosomal maintenance 1

CRPC

:   castration resistant prostate cancer

EVs

:   extracellular vesicles

FASN

:   fatty acid synthetase N

IHC

:   immunohistochemistry

LC

:   liquid chromatography

LFQ

:   label free quantification

MS

:   mass spectrometry

NAP

:   normal adjacent prostate

PCa

:   prostate cancer

PDCD6IP

:   programmed cell death 6 interacting protein; also known as ALIX

PSA

:   prostate specific antigen

RNA

:   ribonucleic acid

TMA

:   tissue microarray

TURP

:   transurethral resection of the prostate

XPO1

:   exportin‐1

1. INTRODUCTION {#pros23813-sec-0050}
===============

Biomarker discovery via extracellular vesicles (EVs; often referred to as exosomes) released by (cancer) cells, has been the focus of many research groups in the last decade.[1](#pros23813-bib-0001){ref-type="ref"}, [2](#pros23813-bib-0002){ref-type="ref"} Based on their biogenesis and secretion pathway, they contain low‐abundant, cancer‐specific proteins, and RNAs that could be of interest in identifying novel biomarkers.[3](#pros23813-bib-0003){ref-type="ref"} With respect to prostate cancer (PCa), several EV‐derived candidate biomarkers have been revealed.[4](#pros23813-bib-0004){ref-type="ref"}, [5](#pros23813-bib-0005){ref-type="ref"}, [6](#pros23813-bib-0006){ref-type="ref"}, [7](#pros23813-bib-0007){ref-type="ref"}, [8](#pros23813-bib-0008){ref-type="ref"}, [9](#pros23813-bib-0009){ref-type="ref"}, [10](#pros23813-bib-0010){ref-type="ref"}

Although multiple markers have been proposed as candidates for several malignancies, the majority has been identified and validated in EVs derived from cell culture. Few of the candidate biomarkers have been validated on larger groups of patient samples. Because this validation step is rarely taken, it remains difficult to elucidate the full potential of EV markers, which limits its translation and clinical implementation.[11](#pros23813-bib-0011){ref-type="ref"}, [12](#pros23813-bib-0012){ref-type="ref"}

Our own efforts, by using state‐of‐the‐art mass spectrometry, has led to the discovery of some candidate markers of which XPO1 (also known as CRM1), FASN, and PDCD6IP (also known as ALIX) were found to have the highest potential.[7](#pros23813-bib-0007){ref-type="ref"} The objective of this study was to investigate whether the PCa EV‐associated expression could be reproduced in tissue analyses of larger cohorts of patients. Result for FASN has been published previously.[13](#pros23813-bib-0013){ref-type="ref"}

2. MATERIALS AND METHODS {#pros23813-sec-0060}
========================

2.1. Mass spectrometry {#pros23813-sec-0070}
----------------------

Protein fractions from tissue RNA isolations with RNA‐Bee of 67 PCa tissue samples (33 NAP and 34 PCa) were selected and stored at −80°C as described in Rodriguez et al.[13](#pros23813-bib-0013){ref-type="ref"} Samples were thawed and 50 µL precipitated with cold acetone and microcentrifugation. After 10 minutes, the supernatant was removed and the pellet washed twice with cold acetone. The supernatant was removed and 50 µL of 0.1% RapiGest (Waters Corporation, Milford, MA) in 50 mM NH~4~HCO~3~ was added to the protein pellet. The protein pellet was dissolved by external sonification for 5 minutes at 70% amplitude at room temperature (Digital Sonifier model 450, Branson, Danbury, CT). The proteins were reduced with 10 mM dithiothreitol at 60°C for 30 minutes. After cooling down to room temperature, it was alkylated with 50 mM iodoacetamide for 30 minutes, and digested overnight with 8 µL trypsin (Promega, Madison, WI). Subsequently, 6 µL of 5% TFA was added to inactivate digestion and incubated for 30 minutes at 37°C. Samples were centrifuged at maximum speed for 60 minutes at 4°C and the supernatant was transferred to new tubes. A total of 5 µL was diluted 40 times and subsequently transferred to LC vials for LC‐MS analysis. Upon analysis, 2 µL was injected to the nano‐LC. After preconcentration and washing of the sample it was loaded on to a C18 column (PepMap C18, 75 mm ID × 500 mm, 2 μm particle, and 100 Å pore size; Thermo Fisher Scientific, Bremen, Germany) using a linear 90 minutes gradient (4%‐25% acetonitrile/H20; 0.1% formic acid) at a flow rate of 250 nL/minute. The separation of the peptides was monitored by a UV detector (absorption at 214 nm). The nano‐LC was coupled to a nanospray source of a Q‐Exactive plus mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Full scan MS spectra (m/z 400‐1600) in profile mode were acquired in the Orbitrap with a resolution of 70 000 after the accumulation of an AGC target of 1 × 10^6^. The top 12 peptide signals (charge‐state 2^+^ and higher) were isolated (1.6 Da window) and fragmented by HCD (higher‐energy collision, normalized collision energy 28.0) and measured in the Orbitrap with an AGC target of 50 000 and a resolution of 17 500. Maximum fill times were 100 ms for the full scans and 60 ms for the MS/MS scans. The dynamic exclusion was activated, after the first time a precursor was selected for fragmentation it was excluded for a period of 30 seconds using a relative mass window of 10 ppm. Lock mass correction was activated to improve mass accuracy of the survey scan.

Label‐free quantitation was performed using Progenesis LC‐MS Software (version 3.0; Nonlinear Dynamics Ltd., Newcastle‐upon‐Tyne, UK) following our previously reported methodology.[14](#pros23813-bib-0014){ref-type="ref"}, [15](#pros23813-bib-0015){ref-type="ref"} To get quantitative data, we selected only proteins identified by three or more peptides for statistical analysis of protein abundance between groups. Duplicates in identified sequences as a consequence of peak tailing were removed to avoid false positives. Technical replicates of each sample were randomly analyzed within the measurement period and no significant changes in the number of identified proteins were observed between replicates and quality control measurements.

2.2. Tissue microarray {#pros23813-sec-0080}
----------------------

A tissue microarray (TMA) was constructed as published previously.[16](#pros23813-bib-0016){ref-type="ref"} Briefly, 481 men were selected from the European Randomized Study of Screening for prostate cancer (ERSPC), who had undergone radical prostatectomy for PCa.[17](#pros23813-bib-0017){ref-type="ref"} From each patient sample, three representative cores (diameter 0.6 mm) were taken and placed in nine paraffin blocks. Patient information and clinical follow data were recorded via the ERSPC protocol and stored in a central study database.

For immunohistochemical (IHC) staining the tissues slides were mounted on aminoacetylsilane coated glass slides (Starfrost, Berlin, Germany), deparaffinized with xylene and dehydrated in ethanol. The slides were placed in 0.3% hydrogen peroxide in PBS for 20 minutes to block endogenous peroxidase activity. Microwave pretreatment was performed for 15 minutes in tris (hydroxymethyl)aminomethane‐ethylenediaminetetraacetic acid (pH 9.0). Subsequently, the slides were incubated with PDCD6IP (1:400), FASN (1:50), and XPO1 (1:50) antibodies, overnight at 4°C. The EnVision DAKO kit (DAKO, Glostrup, Denmark) was used for chromogenic visualization. Counterstaining was performed with hematoxylin, which was followed by dehydration and mounting in malinol (Chroma‐Geselschaft, Körgen, Germany).

Staining intensities of each antibody were scored independently by two investigators (DD, AMH) as negative (0; no staining), weak (1; only visible at high magnification), moderate (2; visible at low magnification), and strong (3; striking at low magnification).[18](#pros23813-bib-0018){ref-type="ref"} Based on previous IHC staining results, for XPO1 a score was assigned to both nuclear staining and cytoplasmic staining.[7](#pros23813-bib-0007){ref-type="ref"} For PDCD6IP only the cytoplasmic expression was scored. In cases of staining heterogeneity, the highest expression levels were used for statistical analysis. After scoring, the average intensity for the triplicate cores was calculated. When a core was missing or no cancer was observed, this respective case was excluded from the analysis. In a combined session consensus on expression value was reached in all cases.

Statistical association of staining intensities and clinic‐pathological features (PSA at diagnosis, Gleason score (GS), pT‐stage, surgical margins, biochemical recurrence, local recurrence, overall death, and PCa‐related death) were performed with SPSS (version 17, SPSS Inc., Chicago, IL) by using Pearson\'s χ^2^ tests and Student\'s *t* tests. A multivariable analysis was performed to determine the contribution of each individual variable. A *P*‐ \< 0.05 was considered to be statistically significant.

3. RESULTS {#pros23813-sec-0090}
==========

3.1. Protein expression by mass spectrometry {#pros23813-sec-0100}
--------------------------------------------

We previously published a list with proteins (n = 263) that were identified in EVs from normal prostate (PNT2C2 and RWPE‐1) and PCa (VCaP and PC346c) cell lines by using mass spectrometry.[7](#pros23813-bib-0007){ref-type="ref"} From this list, 10 proteins were identified as higher expressed in PCa‐derived EVs of which expression of 3 proteins (XPO1, FASN, and PDCD6IP) were further analyzed for EV and tissue expression. For a first validation, we compared the 263 proteins to a shotgun mass spectrometry database recently published which 34 PCa (n = 22 GS 6, n = 12 GS≥ 7) and 33 NAP tissues were compared using label‐free quantification.[19](#pros23813-bib-0019){ref-type="ref"} In this database, a total of 2865 proteins were identified from which 798 proteins were statistically significant differentially expressed between normal prostate and PCa (FDR \< 0.01). When compared to the list of EV‐derived proteins, 42 of these proteins showed overlap (Figure [1](#pros23813-fig-0001){ref-type="fig"}A and Table [1](#pros23813-tbl-0001){ref-type="table"}).

![A, Overlap of proteins between the discovery set of extracellular vesicle‐associated proteins (n = 263)[7](#pros23813-bib-0007){ref-type="ref"} and the proteins differentially expressed between prostate cancer (PCa) and normal adjacent prostate (NAP) tissue (n = 798).[13](#pros23813-bib-0013){ref-type="ref"} B, Protein expression (LOG10 normalized) of XPO1 and PDCD6IP in NAP (n = 33) and PCa tissue (n = 34) and in C, Gleason score \< 7 (n = 22) vs Gleason score ≥ 7 (n = 12) \[Color figure can be viewed at wileyonlinelibrary.com\]](PROS-79-1032-g001){#pros23813-fig-0001}

###### 

Proteins that were significantly differentially expressed between extracellular vesicles (EVs) from prostate cancer (PCa) cells and non‐PCa cells[7](#pros23813-bib-0007){ref-type="ref"} compared to MS‐MS protein expression in PCa and NAP tissue[13](#pros23813-bib-0013){ref-type="ref"}

                                                                                   Accession number                                    Peptide count   Unique peptides   Confidence score   ANOVA (p)   Max fold change   Highest mean expression   Lowest mean expression
  -------------------------------------------------------------------- ----------- --------------------------------------------------- --------------- ----------------- ------------------ ----------- ----------------- ------------------------- ------------------------
  Higher expression in VCaP and PC346c PCa‐derived EVs                                                                                                                                                                                              
  Fatty acid synthase                                                  FASN        P49327                                              103             98                147,44             0,000000    2,95              PCa                       NAP
  Exportin‐1                                                           XPO1        O14980                                              7               7                 7,92               0,000001    1,52              PCa                       NAP
  Polyadenylate‐binding protein 1                                      PABPC1      P11940                                              14              11                16,92              0,001511    1,43              NAP                       PCa
  CD9 antigen                                                          CD9         P21926                                              4               4                 7,98               0,050249    1,30              NAP                       PCa
  Programmed cell death 6‐interacting protein                          PDCD6IP     Q8WUM4                                              30              27                35,77              0,245175    1,10              PCa                       NAP
  Elongation factor 1‐α 2                                              EEF1A2      Q05639                                              13              5                 17,92              0,235288    2,23              PCa                       NAP
  Ubiquitin‐60S ribosomal protein L40                                  UBA52       P62987                                              7               1                 10,96              0,309769    3,36              PCa                       NAP
  Basal cell adhesion molecule                                         BCAM        P50895                                              11              10                12,95              0,472126    1,23              PCa                       NAP
  Vacuolar protein sorting‐associated protein 28 homolog               VPS28       not identified by mass‐spectrometry in PCa tissue                                                                                                                
  Actin‐related protein 3B                                             ACTR3B      not identified by mass‐spectrometry in PCa tissue                                                                                                                
  Higher expression in PNT2C2 and RWPE‐1 normal prostate‐derived EVs                                                                                                                                                                                
  Annexin A2(P07355)                                                   ANXA2       P07355;A6NMY6                                       28              28                38,85              0,000000    1,50              NAP                       PCa
  UDP‐glucose 6‐dehydrogenase(O60701)                                  UGDH        O60701                                              24              22                31,86              0,000000    2,03              PCa                       NAP
  Ras‐related protein Rap‐1A(P62834)                                   RAP1A       P62834                                              8               1                 8,92               0,000011    1,69              NAP                       PCa
  14‐3‐3 protein theta(P27348)                                         YWHAQ       P27348                                              20              12                24,89              0,000201    1,33              PCa                       NAP
  T‐complex protein 1 subunit epsilon(P48643)                          CCT5        P48643                                              17              14                18,87              0,000301    1,43              PCa                       NAP
  78 kDa glucose‐regulated protein(P11021)                             HSPA5       P11021                                              36              28                49,82              0,000304    1,47              PCa                       NAP
  Chloride intracellular channel protein 1(O00299)                     CLIC1       O00299                                              13              12                17,94              0,000486    1,22              PCa                       NAP
  Keratin, type I cytoskeletal 9(P35527)                               KRT9        P35527                                              4               4                 3,93               0,000631    5,87              PCa                       NAP
  14‐3‐3 protein epsilon(P62258)                                       YWHAE       P62258                                              22              19                24,87              0,010096    1,27              PCa                       NAP
  Sodium/potassium‐transporting ATPase subunit β‐3(P54709)             ATP1B3      P54709                                              4               4                 4,98               0,026991    1,16              PCa                       NAP
  Ras‐related protein Rab‐10(P61026)                                   RAB10       P61026                                              6               3                 6,98               0,028100    1,24              PCa                       NAP
  Pyruvate kinase isozymes M1/M2(P14618)                               PKM2        P14618                                              29              29                45,85              0,030393    1,10              NAP                       PCa
  Ras‐related protein Rab‐1A(P62820)                                   RAB1A       P62820                                              8               3                 10,95              0,033276    1,19              PCa                       NAP
  α‐Enolase(P06733)\*                                                  ENO1        P06733                                              30              20                44,82              0,043375    1,22              PCa                       NAP
  Hemoglobin subunit β (P68871)                                        HBB         P68871;P69891;P69892                                18              11                35,87              0,043867    1,53              NAP                       PCa
  Peroxiredoxin‐1(Q06830)                                              PRDX1       Q06830                                              15              11                19,92              0,083975    1,17              PCa                       NAP
  ADP‐ribosylation factor 1(P84077)                                    ARF1        P84077                                              10              3                 11,96              0,132790    1,22              PCa                       NAP
  Keratin, type II cytoskeletal 2 epidermal(P35908)                    KRT2        P35908                                              6               1                 6,96               0,150597    1,24              NAP                       PCa
  Sodium/potassium‐transporting ATPase subunit β‐1(P05026)             ATP1B1      P05026                                              1               1                 1,98               0,186607    1,10              NAP                       PCa
  Catenin β‐1(P35222)                                                  CTNNB1      P35222                                              19              13                21,91              0,190862    1,14              PCa                       NAP
  Ras GTPase‐activating‐like protein IQGAP1(P46940)                    IQGAP1      P46940                                              33              28                37,85              0,198229    1,12              PCa                       NAP
  Ras‐related C3 botulinum toxin substrate 1(P63000)                   RAC1        P63000                                              6               2                 7,97               0,216742    1,14              PCa                       NAP
  Phosphoglycerate kinase 1(P00558)                                    PGK1        P00558                                              28              26                42,79              0,246349    1,06              NAP                       PCa
  Sodium/potassium‐transporting ATPase subunit α‐1(P05023)             ATP1A1      P05023                                              28              25                32,83              0,346299    1,07              PCa                       NAP
  14‐3‐3 protein beta/alpha(P31946)                                    YWHAB       P31946                                              15              7                 19,93              0,370719    1,07              PCa                       NAP
  Tubulin α‐1A chain(Q71U36)                                           TUBA1A      Q71U36;A6NHL2                                       25              2                 37,82              0,377593    1,06              PCa                       NAP
  Lactadherin(Q08431)                                                  MFGE8       Q08431                                              1               1                 1,00               0,518547    1,37              PCa                       NAP
  EH domain‐containing protein 4(Q9H223)                               EHD4        Q9H223                                              8               6                 7,95               0,533687    1,02              PCa                       NAP
  Triosephosphate isomerase(P60174)                                    TPI1        P60174                                              17              15                30,90              0,560817    1,05              PCa                       NAP
  Importin subunit β‐1(Q14974)                                         KPNB1       Q14974                                              16              16                18,91              0,592615    1,04              PCa                       NAP
  Basigin(P35613)                                                      BSG         P35613                                              3               3                 2,94               0,744475    1,03              NAP                       PCa
  Junctional adhesion molecule A(Q9Y624)                               F11R        Q9Y624                                              3               3                 2,98               0,767732    1,07              PCa                       NAP
  Protein DJ‐1(Q99497)                                                 PARK7       Q99497                                              16              15                21,89              0,790992    1,01              NAP                       PCa
  Adenosylhomocysteinase (P23526)                                      AHCY        P23526                                              20              18                23,85              0,906165    1,01              PCa                       NAP
  Integrin α‐6(P23229)                                                 ITGA6       not identified by mass‐spectrometry in PCa tissue                                                                                                                
  Actin, aortic smooth muscle(P62736)                                  ACTA2       not identified by mass‐spectrometry in PCa tissue                                                                                                                
  Potassium‐transporting ATPase α chain 2(P54707)                      ATP12A      not identified by mass‐spectrometry in PCa tissue                                                                                                                
  4F2 cell‐surface antigen heavy chain(P08195)                         SLC3A2      not identified by mass‐spectrometry in PCa tissue                                                                                                                
  CD151 antigen(P48509)                                                CD151       not identified by mass‐spectrometry in PCa tissue                                                                                                                
  Coxsackievirus and adenovirus receptor(P78310)                       CXADR       not identified by mass‐spectrometry in PCa tissue                                                                                                                
  Prostaglandin F2 receptor negative regulator(Q9P2B2)                 PTGFRN      not identified by mass‐spectrometry in PCa tissue                                                                                                                
  Putative heat shock protein HSP 90‐β2(Q58FF8)                        HSP90AB2P   not identified by mass‐spectrometry in PCa tissue                                                                                                                
  Putative heat shock protein HSP 90‐β‐3(Q58FF7)                       HSP90AB3P   not identified by mass‐spectrometry in PCa tissue                                                                                                                

Abbreviation: NAP, normal adjacent prostate.

John Wiley & Sons, Ltd.

Our previously identified candidate PCa‐EV biomarkers XPO1 (*P* \< 0.0001) and FASN (*P* \< 0.0001) were higher expressed in PCa tissue, while PDCD6IP was borderline not significantly higher expressed (*P* = 0.0501) (Table [1](#pros23813-tbl-0001){ref-type="table"}; Figure [1](#pros23813-fig-0001){ref-type="fig"}B). Interestingly, polyadenylate‐binding protein 1 (PABCP1) was higher expressed in PCa‐derived EVs but showed significantly lower expression in PCa tissue when compared to NAP (*P* = 0.0015). Four other proteins (CD9, EEF1A2, UBA52, and BCAM) were not significantly differentially expressed in the tissue proteomics. The PCa‐derived EV proteins VPS28 and ACTR3B were not identified in the tissue validation set. Proteins that were higher expressed in normal prostate cell line EVs were also cross‐validated on MS‐MS data of tissue samples and are shown in Table [1](#pros23813-tbl-0001){ref-type="table"}. Although 15 of the 34 were differentially expressed in both datasets, only 4 of the 15 showed the same direction of higher expressed in EVs from immortalized normal prostate epithelial cell lines and higher expressed in NAP tissue.

When expression of proteins was compared, XPO1 was significantly higher expressed in PCa (Figure [1](#pros23813-fig-0001){ref-type="fig"}B), but no difference (*P* = 0.696) was observed between low risk (GS 6) and intermediate/high‐risk PCa (GS ≥ 7) (Figure [1](#pros23813-fig-0001){ref-type="fig"}C). Interestingly, PDCD6IP was significantly lower expressed in intermediate/high risk in prostate tissue (*P* = 0.017) (Figure [1](#pros23813-fig-0001){ref-type="fig"}C).

3.2. Protein expression by tissue microarray immunohistochemistry {#pros23813-sec-0110}
-----------------------------------------------------------------

For independent validation of XPO1 and PDCD6IP, immunohistochemistry (IHC) was performed on the TMA. Patient characteristics and clinicopathological parameters are shown in Table [2](#pros23813-tbl-0002){ref-type="table"} and were previously published by Hoogland et al.[16](#pros23813-bib-0016){ref-type="ref"} Briefly, the mean age at the time of radical prostatectomy was 64.7 years; follow‐up was 113.3 months. Gleason score after radical prostatectomy was \<7 in 265 (55.1%), 7 in 188 (39.1%), and \>7 in 28 (5.8%) patients. Surgical margins were negative in 362 (75.3%) patients. Biochemical recurrence was observed in 119 (24.7%) patients after an average of 40.9 months. Staining intensities of the candidate biomarkers could not be assessed in 57 of the 481 samples (11.8%) because the tumor was absent.

###### 

Patient characteristics and clinicopathological parameters of the prostate samples after treatment by radical prostatectomy (n = 481) as was published by Hoogland et al[16](#pros23813-bib-0016){ref-type="ref"}

  Patient characteristics and clinico‐pathological parameters   Total number of patients (%)   Mean (variation)
  ------------------------------------------------------------- ------------------------------ ------------------
  Age at diagnosis, y                                                                          64.5 (55‐75)
  \>60                                                          n = 411 (85.4)                 
  \>65                                                          n = 260 (54.0)                 
  \>70                                                          n = 57 (10.6)                  
  Follow‐up, mo                                                                                113.3 (0‐204)
  PSA levels at diagnosis, ng/mL                                                               7.2 (0.3‐125)
  \>2.5                                                         n = 440 (91.5)                 
  \>4                                                           n = 333 (69.2)                 
  \>10                                                          n = 62 (12.9)                  
  Gleason sum                                                                                  
  \<7                                                           n = 199 (41.4)                 
  =7                                                            n = 188 (39.1)                 
  \>7                                                           n = 28 (5.8)                   
  Pathological T‐stage (TNM 2002)                                                              
  T2a                                                           n = 84 (17.5)                  
  T2b                                                           n = 10 (2.1)                   
  T2c                                                           n = 246 (51.1)                 
  T3a                                                           n = 93 (19.3)                  
  T3b                                                           n = 17 (3.5)                   
  T4                                                            n = 28 (5.8)                   
  Surgical margins                                                                             
  Positive                                                      n = 119 (24.7)                 
  Negative                                                      n = 362 (75.3)                 
  Biochemical recurrence, mo                                                                   40.9 (0‐205)
  Yes                                                           n = 119 (24.7)                 
  No                                                            n = 362 (75.3)                 
  Local recurrence, mo                                                                         110.0 (6‐146)
  Yes                                                           n = 24 (5.0)                   
  No                                                            n = 457 (95.0)                 
  Overall death, mo                                                                            113.7 (0‐202)
  Yes                                                           n = 112 (23.3)                 
  No                                                            n = 368 (76.6)                 
  Prostate cancer related death                                                                
  Yes                                                           n = 12 (10.7)                  
  No                                                            n = 74 (66.0)                  
  Unknown                                                       n = 26 (23.2)                  

Abbreviation: PSA, prostrate specific antigen.

John Wiley & Sons, Ltd.

Antibody IHC verification and impression of the tissue staining of the three candidate protein markers was published previously and further expanded as depicted in Figure [2](#pros23813-fig-0002){ref-type="fig"}.[7](#pros23813-bib-0007){ref-type="ref"} XPO1, PDCD6IP, and FASN stainings were observed in all samples, mainly in epithelial cells. We noticed that the XPO1 expression varied within and between the nuclear and cytoplasmic compartments. Nuclear XPO1 expression was present in 98.4% of cases and cytoplasmic expression was observed in 74.5% of cases. XPO1 showed strong nuclear and low cytoplasmic expression in luminal cells in NAP.[7](#pros23813-bib-0007){ref-type="ref"} With the progression of PCa and increasing GS, cytoplasmic XPO1 expression increased (Figure [2](#pros23813-fig-0002){ref-type="fig"}). PDCD6IP showed high expression in both luminal and basal cells in NAP.

![Immunohistochemical staining of XPO1, FASN, and PDCD6IP on normal adjacent prostate (NAP) and prostate cancer (PCa) with increasing Gleason scores (GS). Picture was partially published before.[7](#pros23813-bib-0007){ref-type="ref"} \[Color figure can be viewed at wileyonlinelibrary.com\]](PROS-79-1032-g002){#pros23813-fig-0002}

Subsequently, we evaluated the association between protein expression intensities of our three candidate biomarkers and PSA at diagnosis, GS, pT‐stage, surgical margins, biochemical recurrence, local recurrence, overall death and PCa‐related death (Tables [3](#pros23813-tbl-0003){ref-type="table"}, [4](#pros23813-tbl-0004){ref-type="table"}; Table S1). Nuclear XPO1 expression and PDCD6IP did not correlate with any clinicopathological parameter. High cytoplasmic XPO1 expression correlated with GS ≥ 7 (*P* = 0.002) and PCa‐specific death after multivariate analysis (*P* = 0.009) (Table [4](#pros23813-tbl-0004){ref-type="table"}). All other parameters were not significantly different. The FASN TMA analyses have recently been published as part of the tissue proteomics study and revealed that expression among the PCa samples was higher in GS \< 7 and GS = 7 (49.0% and 34.6%, respectively) than in GS \> 7 (5.4%). This is in agreement with previous studies.[6](#pros23813-bib-0006){ref-type="ref"}, [19](#pros23813-bib-0019){ref-type="ref"}

###### 

Scored staining intensity and distribution of the cytoplasmic and nuclear XPO1 in our tissue microarray

  Expression nuclear XPO1   0     1     2     3     Total   *P*‐value
  ------------------------- ----- ----- ----- ----- ------- -----------
  PSA at diagnosis                                          
  ≤10 ng/mL                 5     66    217   119   396     0.012
  \>10 ng/mL                1     16    35    8     60      
  Total                     6     71    252   127   456     
  Gleason score                                             
  \<7                       5     40    129   74    248     0.145
  7                         0     26    105   50    181     
  \>7                       1     5     19    3     28      
  Total                     6     71    253   127   457     
  pT‐stage                                                  
  pT2                       5     49    177   93    324     0.345
  pT3a/b                    1     14    65    26    106     
  pT4                       0     8     11    8     27      
  Total                     6     71    253   127   457     
  PSA at diagnosis                                          
  ≤10 ng/mL                 104   236   55    1     396     0.920
  \>10 ng/mL                15    38    7     0     60      
  Total                     119   274   62    1     456     
  Gleason score                                             
  \<7                       79    146   23    0     248     0.002
  7                         40    109   31    1     181     
  \>7                       1     19    8     0     28      
  Total                     120   274   62    1     457     
  pT‐stage                                                  
  pT2                       92    195   36    1     324     0.221
  pT3a/b                    23    61    22    0     106     
  pT4                       5     18    4     0     27      
  Total                     120   274   62    1     457     

Intensity was scored as negative (0; no staining), weak (1; only visible at high magnification), moderate (2; visible at low magnification), or strong (3; striking at low magnification). Staining intensities were correlated with patient characteristics after radical prostatectomy

Abbreviation: PSA, prostrate specific antigen.

John Wiley & Sons, Ltd.

###### 

Univariate and multivariate correlation of clinicopathological parameters and staining intensities of PDCD6IP, nuclear XPO1, and cytoplasmic XPO1. A *P* \< 0.05 was considered as statistically significant

                    PSA         Gleason score   pT stage    Biochemical recurrence   Local recurrence   Death              Prostate specific death                                                                                                                                                                                 
  ----------------- ----------- --------------- ----------- ------------------------ ------------------ ------------------ ------------------------- ------------------ ----------- ------------------ ----------- ------------------ ----------- ------------------ ----------- ------------------ ----------- ------------------ -----------
                    *P*‐value   *P*‐value       *P*‐value   HR                       *P*‐value          HR                 *P*‐value                 HR                 *P*‐value   HR                 *P*‐value   HR                 *P*‐value   HR                 *P*‐value   HR                 *P*‐value   HR                 *P*‐value
  Nuclear XPO1      0.012       0.145           0.345       0.97 (0.75‐1.26)         0.831              0.97 (0.75‐1.26)   0.831                     0.59 (0.32‐1.06)   0.079       0.59 (0.31‐1.12)   0.109       1.08 (0.83‐1.41)   0.575       1.10 (0.83‐1.46)   0.520       0.96 (0.42‐2.17)   0.913       1.70 (0.56‐5.17)   0.351
  Cytoplasmic XPO   0.920       0.002           0.221       1.04 (0.77‐1.41)         0.783              1.04 (0.77‐1.41)   0.783                     1.30 (0.65‐2.62)   0.462       1.03 (0.49‐2.12)   0.946       1.14 (0.84‐1.54)   0.413       1.11 (0.80‐1.53)   0.546       1.90 (0.92‐3.19)   0.084       3.03 (1.33‐6.93)   0.009
  PDCD6IP           0.490       0.581           0.439       1.16 (0.83‐1.64)         0.386              1.16 (0.83‐1.64)   0.386                     1.22 (0.54‐2.79)   0.631       1.51 (0.65‐3.54)   0.340       1.04 (0.74‐1.46)   0.825       1.05 (0.75‐1.49)   0.765       1.05 (0.39‐2.81)   0.926       1.50 (0.39‐5.74)   0.558

Abbreviation: HR, hazards ratio; PSA, prostrate specific antigen.

John Wiley & Sons, Ltd.

4. DISCUSSION {#pros23813-sec-0120}
=============

In this study we investigated whether previously identified PCa EV‐derived proteins were differentially expressed in PCa tissue from patients using mass spectrometry and immunohistochemistry. We found that XPO1 was associated with PCa in mass spectrometry and with higher GS using IHC on our TMA. PDCD6IP was not associated with adverse clinicopathological characteristics.

XPO1 (also known as CRM1) mediates nuclear export of proteins and RNAs and its differential expression has been linked to multiple types of cancer.[20](#pros23813-bib-0020){ref-type="ref"}, [21](#pros23813-bib-0021){ref-type="ref"}, [22](#pros23813-bib-0022){ref-type="ref"} These transported proteins play a role in tumor signaling pathways, including the AR‐pathway.[23](#pros23813-bib-0023){ref-type="ref"}, [24](#pros23813-bib-0024){ref-type="ref"} XPO1 has already been identified as a marker for several malignancies.[21](#pros23813-bib-0021){ref-type="ref"} We identified this protein to be higher expressed in EVs derived from the VCaP PCa cell line.[7](#pros23813-bib-0007){ref-type="ref"} In this current study, we observed higher expression in PCa tissue as compared to NAP, which could explain the increased EV expression. From the TMA, we noticed that when GS increased, nuclear staining decreased and cytoplasmic XPO1 location increased. This provides us with an additional explanation for the increased presence of this 123 kDa nuclear export protein in EVs: a shift towards cytoplasmic expression could increase the random chance or even active escorting of XPO1 into extracellular vesicles.

When correlated to clinicopathological parameters, we observed a significant correlation between higher XPO1 cytoplasmic expression with higher GS (7 or higher) and disease‐specific death. Therefore, this finding implies that there seems to be a clinical role as a tissue marker regarding prognosis for PCa. The correlation with disease‐specific death could only be addressed in 12 patients. Because of the limited number of patients with PCa‐related death, we should be careful to draw conclusions regarding the correlation of cytoplasmic XPO1 and this clinical parameter.

Interestingly, recent reports have been published on the functional role of XPO1 and the effect of cancer by inhibition of XPO1‐mediated transport. Administration of selective inhibitors of nuclear transport (SINE) such as Selinexor, have led to an enrichment of tumor suppressor proteins in the nucleus.[25](#pros23813-bib-0025){ref-type="ref"} This subsequently resulted in apoptosis, reduction of tumor spreading and improved overall survival in preclinical models in PCa.[26](#pros23813-bib-0026){ref-type="ref"}, [27](#pros23813-bib-0027){ref-type="ref"}, [28](#pros23813-bib-0028){ref-type="ref"} Clinical studies are being performed to reveal the real potential of XPO1‐directed therapy.

FASN has already been described as a potential marker for PCa.[29](#pros23813-bib-0029){ref-type="ref"}, [30](#pros23813-bib-0030){ref-type="ref"} A recent study by Hamada et al[31](#pros23813-bib-0031){ref-type="ref"}, showed that expression of this protein on biopsies could be a marker for the upgrading of GS after radical prostatectomy. Furthermore, Wu et al[32](#pros23813-bib-0032){ref-type="ref"} showed that this protein is useful for the diagnosis of PCa. However, both studies were performed on relatively small groups (\<100 patient samples). Although we previously showed higher expression of FASN in PCa EVs, Rodriguez‐Blanco et al[19](#pros23813-bib-0019){ref-type="ref"}, could only observe a statistically significant difference with normal prostate tissue in our TMA. When expression was compared with clinicopathological parameters, no statistically significant difference was observed. So far, FASN could be used as a marker for the diagnosis PCa, but the expression in normal cells is also relatively high. This makes it difficult for distinguishing between disease and healthy tissue.

PDCD6IP has scarcely been reported as a tumor marker or as having a role in tumor biology. PDCD6IP (also referred to as ALIX) is involved in endocytosis, multivesicular body biogenesis, apoptosis, membrane repair, and directly related to EV formation.[33](#pros23813-bib-0033){ref-type="ref"}, [34](#pros23813-bib-0034){ref-type="ref"} Although PDCD6IP is used as a general marker for EVs, the transformation of healthy cells to cancerous cells could interfere with EV formation and therefore the presence of PDCD6IP could be altered. Our current study showed no statistical difference of expression between NAP and PCa tissue, nor did we find decreased PDCD6IP expression in patients with GS≥7 in our TMA. Furthermore, PDCD6IP did not correlate to any clinicopathological parameters. We conclude that over‐representation of PDCD6IP in EVs from VCaP and PC346c is not explained by a general higher expression of this protein in PCa.

Although PDCD6IP differential expression in EVs could not be validated with tissue MS‐MS and TMA IHC, it would be interesting to see whether this marker still shows clinical potential when an easily applicable EV‐specific assay (such as an ELISA) is applied.

From our mass spectrometry and TMA analyses, we have learned that overexpression and cytoplasmic compartmentalization provides an explanation for the increased presence of XPO1 in PCa‐derived EVs. The absence of a correlation between tissue and EV expression for PCDC6IP suggest that also other mechanisms play a role in EV‐mediated secretion. The most obvious would be specific escorting of proteins in extracellular vesicles via the ESCRT system.[35](#pros23813-bib-0035){ref-type="ref"}, [36](#pros23813-bib-0036){ref-type="ref"} Whether this pathway is changed in cancer development and progression is not fully known.[37](#pros23813-bib-0037){ref-type="ref"}

Besides XPO1, FASN, and PDCD6IP, our analyses also provided more data for new candidate EV biomarkers: The 16 additional proteins that were identified in EVs and also differentially expressed in the tissue MS analyses. It is worthwhile to investigate whether these PCa tissue‐dysregulated, EV‐detectable proteins are EV biomarkers in other cell lines and in clinical samples. From this list, PABPC1, CLIC1, RAB10, and PKM2 have been identified as a potential marker for (prostate) cancer. [38](#pros23813-bib-0038){ref-type="ref"}, [39](#pros23813-bib-0039){ref-type="ref"}, [40](#pros23813-bib-0040){ref-type="ref"}, [41](#pros23813-bib-0041){ref-type="ref"} High expression of ANXA2 has been shown to have an unfavorable prognosis in multiple malignancies.[42](#pros23813-bib-0042){ref-type="ref"} Within this group of potential biomarkers, it is of interest to note that the level of expression in EVs from normal versus PCa cell lines is not always in the same direction as the NAP versus PCa tissue MS (Table [1](#pros23813-tbl-0001){ref-type="table"}). Besides the comparison of a few 2D grown cell lines with patient tissue samples, changes in cytoplasmic subcellular location and specific EV sorting of proteins can explain such apparent discrepancies.

XPO1, FASN, and PCDC6IP are known or expected to be intra‐vesicular proteins and a detection assay to determine their levels in EVs from bodyfluids will likely involve multiple steps: EV isolation and disruption followed by protein measurement using enzyme‐linked immunosorbent assays (ELISA), related immune‐assays or mass spectrometry.[3](#pros23813-bib-0003){ref-type="ref"}, [43](#pros23813-bib-0043){ref-type="ref"} Robust and reproducible EV isolation and protein assays are still under development and until these technologies are standardized, large scale intra‐vesicular protein biomarker validation and clinical implementation are difficult to realize. This is different for EV membrane‐associated proteins that can be detected with antibodies while the vesicle remains intact. Standard ELISA‐like assays might capture and detect the EV protein of interest, directly from biofluids.[12](#pros23813-bib-0012){ref-type="ref"}, [43](#pros23813-bib-0043){ref-type="ref"}

5. CONCLUSIONS {#pros23813-sec-0130}
==============

In this study, we investigated previously‐identified EV‐derived markers on large cohorts of patient tissue samples for validation of diagnostic and prognostic differential expression. High expression of cytoplasmic XPO1 shows a strong correlation with PCa progression, while no differential tissue expression of PDCD6IP was observed. The increase in cytoplasmic XPO1 during the progression of PCa can explain the higher abundance in secreted EVs.
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